Last 29 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.41 | 0.91 | 0.85 | 0.55 | 0.44 | 0.45 | 0.34 | 0.36 | 0.45 | 0.77 | 0.96 | 1.16 | 1.19 | 0.23 | 0.34 | 0.50 | 0.79 | 1.60 | 1.28 | 1.64 | 2.02 |
| — | +99.9% | +147.9% | +52.7% | -2.4% | -41.2% | -64.2% | -69.0% | -62.1% | +235.9% | +184.2% | +130.9% | +50.9% | -85.7% | -73.7% | -69.5% | -61.0% | -52.7% | -64.4% | -53.4% | -67.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.9% | -14.4% | -15.1% | -9.3% | -8.4% | -6.2% | -6.2% | -8.1% | -6.2% | -6.4% | -5.4% | -7.9% | -9.7% | -8.3% | -10.0% | -8.6% | -8.4% | -6.9% | -8.3% | -10.8% | -8.8% |
| — | -130.3% | -142.5% | -14.5% | -36.3% | +2.6% | -15.7% | -2.9% | +36.5% | +23.1% | +46.2% | +7.8% | -15.3% | -20.7% | -20.9% | +20.9% | +3.6% | +13.7% | -14.4% | -75.4% | -60.6% | |
| ROA | -23.0% | -10.3% | -11.4% | -7.2% | -6.6% | -5.0% | -5.0% | -6.6% | -5.0% | -5.2% | -4.4% | -6.2% | -7.1% | -6.1% | -7.5% | -6.6% | -6.7% | -5.6% | -6.6% | -9.0% | -8.1% |
| — | -108.0% | -127.5% | -8.9% | -31.3% | +5.0% | -13.2% | -6.6% | +29.0% | +15.0% | +41.1% | +6.7% | -6.0% | -9.2% | -12.9% | +26.1% | +17.2% | +24.3% | +2.0% | -53.4% | -55.3% | |
| ROIC | -22.5% | -10.0% | -10.3% | -6.8% | -6.6% | -5.6% | -5.2% | -6.3% | -5.0% | -5.8% | -6.3% | -7.7% | -6.9% | -6.0% | -7.2% | -6.4% | -6.1% | -5.6% | -6.7% | -8.5% | -8.8% |
| — | -80.4% | -98.5% | -7.1% | -30.9% | +3.9% | +18.1% | +17.3% | +26.8% | +4.4% | +12.7% | -19.4% | -13.1% | -7.1% | -8.1% | +24.8% | +30.9% | +22.3% | -9.9% | -42.8% | -27.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.33 | 0.30 | 0.26 | 0.24 | 0.23 | 0.22 | 0.21 | 0.20 | 0.20 | 0.19 | 0.18 | 0.32 | 0.30 | 0.28 | 0.26 | 0.22 | 0.21 | 0.17 | 0.30 | 0.05 |
| — | +47.2% | +35.2% | +25.9% | +24.4% | +14.4% | +16.3% | +13.2% | -39.1% | -34.2% | -33.7% | -30.1% | +45.1% | +44.2% | +65.3% | -13.0% | +348.8% | +340.6% | +291.0% | +645.6% | +78.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.69 | 5.79 | 7.98 | 12.96 | 12.69 | 15.23 | 15.67 | 14.48 | 14.45 | 12.91 | 15.91 | 19.95 | 10.85 | 10.97 | 10.77 | 12.79 | 16.36 | 15.17 | 31.66 | 20.59 | 18.99 |
| — | -62.0% | -49.1% | -10.5% | -12.2% | +18.0% | -1.5% | -27.4% | +33.2% | +17.8% | +47.6% | +56.1% | -33.7% | -27.7% | -66.0% | -37.9% | -13.8% | -30.9% | +14.4% | -36.3% | -47.4% | |
| Quick Ratio | 12.69 | 5.79 | 7.98 | 12.96 | 12.69 | 15.23 | 15.67 | 14.48 | 14.45 | 12.91 | 15.91 | 19.95 | 10.85 | 10.97 | 10.77 | 12.79 | 16.36 | 15.17 | 31.66 | 20.59 | 18.99 |
| — | -62.0% | -49.1% | -10.5% | -12.2% | +18.0% | -1.5% | -27.4% | +33.2% | +17.8% | +47.6% | +56.1% | -33.7% | -27.7% | -66.0% | -37.9% | -13.8% | -30.9% | +14.4% | -36.3% | -47.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NKTX stock.
Nkarta, Inc.'s current P/E is -1.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nkarta, Inc.'s business trajectory between earnings reports.